Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Orum Therapeutics wins FDA nod to start phase 1 trial for AML drug

23 August 2026 · By · Wire by Fusion42

Published

23 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biz.chosun.com →

◆ Verified

Fusion42 · 23 August 2026 · Fusion42 review

Orum Therapeutics received FDA approval to start a phase 1 clinical trial of ORM-1153, a novel degradation-activating conjugate drug for relapsed or refractory acute myeloid leukemia (AML) and other blood cancers, with trial sites planned in the US and possibly other regions.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

FDA approval opens a new path for early clinical testing of a first-in-class blood cancer drug, giving you a rare chance to reassess competitive benchmarks and partner with Orum for trial-related innovations.

◆ Coverage

1 source · 23 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalacute-myeloid-leukemiaclinical-trialhematologic-cancersbiotech